Nearly 1 Billion People Worldwide Have Sleep Apnea, International Sleep Experts Estimate
A new data analysis presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conference indicates that the prevalence of sleep apnea impacts more than 936 million people worldwide – nearly 10 times greater than previous estimates.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005096/en/
Woman wearing CPAP, the gold standard treatment for sleep apnea (Photo: Business Wire)
The study “Global Prevalence of Obstructive Sleep Apnea (OSA)” was conducted by an international panel of leading researchers seeking to provide a clear scope of the impact of the chronic sleep-disordered breathing condition. The previous estimation of OSA prevalence (100 million) came from a 2007 World Health Organization study that used methods and data available at the time. By analyzing technology improvements in detecting OSA and underreported statistics from other areas of the world, this latest study depicts an impacted population significantly larger than previously identified.
“The research and findings are a revelation in sleep apnea research and represent a vastly underreported major public health issue,” said Adam Benjafield, ResMed vice president of Medical Affairs and lead study researcher. “This new study demonstrates a need for expanded awareness around the diagnosis and treatment of OSA worldwide.”
Sleep apnea is a chronic disease that causes people to stop breathing while they sleep. To avoid suffocation, the body is jolted by the brain to take a breath, typically without the person ever being aware. This cycle can repeat as many as hundreds of times a night, disrupting normal sleep patterns. Life-threatening conditions associated with OSA range from chronic daytime fatigue to heart disease, stroke, type 2 diabetes, depression, and more. Previous studies have suggested that undiagnosed sleep apnea costs nearly $150 billion in the United States alone as a result of related lost productivity, motor vehicle accidents and workplace accidents – an economic impact that’s likely much greater, given a higher prevalence total.
“This study should encourage physicians to talk with their patients about how sleep affects our overall health,” said ResMed Chief Medical Officer Carlos M. Nunez, M.D. “It should also cause more people to ask themselves, ‘Do I or my bed partner have this?’ Those who have sleep apnea don’t often realize they have it and, therefore, don’t realize they can do something to mitigate the resulting chronic fatigue or its more harmful long-term health risks. And sleep apnea isn’t just a disease for older, overweight men, as once thought. It affects people of all ages, all ethnic and racial groups, all states of health, and is not gender specific. In fact, nearly half of newly diagnosed patients are female.”
About the study
In 2007, The World Health Organization (WHO) estimated more than 100 million people are affected by OSA, although they acknowledged that this figure was not based on robust data.
The aim of this new study, “Global Prevalence of Obstructive Sleep Apnea in Adults: Estimation Using Currently Available Data,” is to estimate the global adult prevalence of OSA. Researchers identified 16 countries with published prevalence papers based on objective sleep studies and applied findings to areas previously under-quantified. After data review, estimates were extrapolated based on the global adult population aged 30–69 years. Prevalence statistics were applied to population numbers in each country based on the corresponding gender and body mass index (a key risk factor for OSA). OSA prevalence was estimated based on severity of the disease as measured by the apnea–hypopnea index.
Convened by ResMed, the experts included representatives from North and South America, Europe, and Asia-Pacific.
ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance22.7.2019 16:00:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo(s)tide or non-nucleo(s)tide reverse transcriptase inhibitors (NRTIs or NNRTIs). The use of Biktarvy in patients with known drug resistance is investigational. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “These data presented at IAS provide new information about the treatment of HIV among women and patients with known drug resistance,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “The studies further demonstrate the potential for Biktarvy to be an
IBC Celebrates Young Talent in the Industry22.7.2019 15:36:00 CEST | Press release
The media, entertainment and technology industry is changing. Attitudes are shifting, the next generation is consuming content differently to any before them and diverse and exciting content is being created to meet that demand in innovative formats. Driving this change is a new wave of industry talent, honoured at IBC with the first IBC Young Pioneer Award. Recognising the brightest, newest talent in the industry, this award will go to someone who has made a real impact with their passion, ambition and commitment and is making an outstanding contribution to our industry. “What we were looking for in the shortlist was, most importantly, real talent, a stand-out individual making a real difference in the industry,” said David Levine, VP, Programming - Kids, Europe & Africa/UK & Ireland, The Walt Disney Co. Ltd and Chair of the Judging Panel. “But we were also looking for a lasting legacy, for the Young Pioneer to be a leader today and a media guru of the future.” The call for entries so
Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV22.7.2019 15:00:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function. The Phase 1b data demonstrate the first proof of concept that HIV capsid inhibition can lead to significant declines in viral load in vivo. In addition, Gilead presented preclinical data demonstrating that resistance to GS-6207 in vitro did not lead to resistance to other classes of drugs used in the treatment of HIV. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. GS-6207 is an investigational long-acting antiretroviral agent that can be delivered subcutaneously. GS-6207 recently received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) as a potential therapy for heavily treatment-experienced people living with multi-drug resistant HIV. GS-6207 acts in a novel way compared with current
Pacific Drilling Appoints James W. Harris as Chief Financial Officer22.7.2019 13:42:00 CEST | Press release
Pacific Drilling S.A. (NYSE: PACD), one of the world’s leading deepwater drilling contractors, today announced that Pacific Drilling’s Board has appointed James W. Harris to serve as the Company’s Senior Vice President and Chief Financial Officer. Mr. Harris replaces Mr. Johannes (John) P. Boots, who, as previously announced, mutually agreed with the Company to step down from his position to pursue other opportunities. Mr. Harris has more than 30 years of experience in the energy industry in a variety of financial leadership, strategic and business planning roles. He most recently served as Executive Vice President, Drilling & Subsea for Forum Energy Technologies, Inc., having previously served Forum as Chief Financial Officer for 12 years. Bernie Wolford, the Company’s Chief Executive Officer, stated, “We sincerely appreciate the many contributions that John has made during his nearly 10-year tenure with Pacific Drilling and we wish him all the best in his future endeavors.” “We are e
Moody’s Analytics Wins Credit Data Provider of the Year at Risk Technology Awards22.7.2019 11:00:00 CEST | Press release
Moody’s Analytics, a global provider of financial intelligence, has won Credit Data Provider of the Year in the 2019 Risk Technology Awards. It’s one of six categories won, spanning finance, accounting, regulatory, and credit functions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005025/en/ The combined strength of Moody’s Analytics offerings earned the Credit Data Provider of the Year award. “We’re honored by this recognition,” said Jacob Grotta, Managing Director-Head of Risk & Finance Analytics. “Credit data challenges take many forms, and our capabilities are exemplified in a range of award-winning solutions.” Our Data Alliance is among the world’s largest and most comprehensive data consortia. Its global contributors share origination and performance data in C&I, CRE, project finance, asset finance, and other asset classes – and in return receive benchmarking across a host of metrics as well as detailed reports
U.N. Environment Programme Urged to Protect Nature and Humankind from Electromagnetic Fields (EMF)22.7.2019 11:00:00 CEST | Press release
The Advisors to the International EMF Scientist Appeal, representing 248 scientists from 42 nations, have resubmitted The Appeal to the United Nations Environment Programme (UNEP) Executive Director, Inger Andersen, requesting the UNEP reassess the potential biological impacts of next generation 4G and 5G telecommunication technologies to plants, animals and humans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005154/en/ Ronald L. Melnick, PhD, who led the design of the large $30 million NIH/NTP Animal Study, which showed Radio Frequency Radiation emitted by cell phones and wireless devices causes cancer, confirms that the previously held assumption the radiation cannot cause cancer, or other adverse health effects, is wrong. (Photo: Business Wire) There is particular urgency at this time as new antennas will be densely located throughout residential neighborhoods using much higher frequencies, with greater biologica